uniQure QURE
NASDAQ QURE
$45.96 +0.28 (+0.61%)
As of: Sep 9, 2026 · 3:59 PM EDT

uniQure (QURE) Cost of Revenue (2021 - 2026)

uniQure (QURE) posted Cost of Revenue of $350000.0 for Q2 2026, up 59.82% on a QoQ basis from $219000.0 in Q1 2026, and down 46.65% year-over-year from $656000.0 in Q2 2025.

Analysis

uniQure (QURE) Cost of Revenue (2021 - 2026) Analysis & Trends

uniQure has reported Cost of Revenue for 6 years, with the latest figure at $350000.0 in Q2 2026.

  • On a quarterly basis, Cost of Revenue fell 46.65% year-over-year to $350000.0 in Q2 2026; TTM through Jun 2026 was $1.4 million, a 12.92% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 90.12% from the prior year.
  • Cost of Revenue was $350000.0 for Q2 2026 at uniQure, up from $219000.0 in the prior quarter.
  • The five-year high for Cost of Revenue was $9.1 million in Q1 2024, with the low at $197000.0 in Q1 2025.
  • Average Cost of Revenue over 5 years is $2.2 million, with a median of $794500.0 recorded in 2022.
  • The sharpest annual moves came in 2023 and 2025: Cost of Revenue jumped 2114.65% in 2023, then plunged 97.83% in 2025.
  • Over 5 years, Cost of Revenue stood at $396000.0 in 2022, then surged by 2114.65% to $8.8 million in 2023, then tumbled by 91.37% to $757000.0 in 2024, then sank by 42.54% to $435000.0 in 2025, then decreased by 19.54% to $350000.0 in 2026.
  • The last three Cost of Revenue figures came in at $350000.0 (Q2 2026), $219000.0 (Q1 2026), and $435000.0 (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Krystal Biotech 10.27 Bn 9.43 Bn 112.79 Mn 6.44 Mn
2 CRISPR Therapeutics AG 5.17 Bn 5.17 Bn - -
3 Iovance Biotherapeutics 3.79 Bn 3.49 Bn 55.72 Mn 43.60 Mn
4 Legend Biotech 3.68 Bn 2.71 Bn 251.50 Mn 136.00 Mn
5 uniQure 3.05 Bn 3.05 Bn 5.49 Mn 350,000.00
6 Beam Therapeutics 2.65 Bn 2.65 Bn - -
7 Precigen 2.44 Bn 2.44 Bn 52.17 Mn 2.81 Mn
8 Sarepta Therapeutics 2.33 Bn 1.53 Bn 251.87 Mn 149.39 Mn
9 Vericel 1.99 Bn 1.83 Bn 56.40 Mn 21.06 Mn
10 Taysha Gene Therapies 1.97 Bn 1.97 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 350,000.00
Mar 31, 2026 219,000.00
Dec 31, 2025 435,000.00
Sep 30, 2025 398,000.00
Jun 30, 2025 656,000.00
Mar 31, 2025 197,000.00
Sep 30, 2024 757,000.00
Jun 30, 2024 7.23 Mn
Mar 31, 2024 9.08 Mn
Dec 31, 2023 8.77 Mn
Sep 30, 2023 1.01 Mn
Jun 30, 2023 1.35 Mn
Mar 31, 2023 2.44 Mn
Dec 31, 2022 396,000.00
Sep 30, 2022 861,000.00
Jun 30, 2022 832,000.00
Dec 31, 2021 1.80 Mn
Jun 30, 2021 23.18 Mn